Disease relevance of beta-Anthraquinonylamine

• Two aminoanthraquinone analogs 1,4-bis(2-[(2-hydroxyethyl)amino]ethylamino)-9,10-anthracenedione (HAQ) and 1,4-dihydroxy-5,8-bis(2-[(2-hydroxyethyl)amino]ethylamino]-9,10-anthracenedione (DHAQ) have been shown to possess similar therapeutic activities against experimental tumors but different toxicities to the animals [1].
• Fourteen eczema patients, 13 women and one man, were found to have contact allergy to a brown stocking dye which is a mixture of nitro- and aminodiazobenzene and aminoanthraquinone dyes [2].
• The synthesis of several aminoanthraquinone derivatives (AAQs), designed to suppress the dark toxicity and to promote more efficient cancer cell photosensitization for potential use in photodynamic therapy (PDT), is described [3].
• Proteinuria in the Fischer rat by feeding 2-aminoanthraquinone [4].

High impact information on beta-Anthraquinonylamine

• Centromere analysis of micronuclei induced by 2-aminoanthraquinone in cultured mouse splenocytes using both a gamma-satellite DNA probe and anti-kinetochore antibody [5].
• 1. Feeding 2-aminoanthraquinone (2-AAQ) in the diet to Fischer rats led to nephrotoxicity in females, caused by deposits of crystalline material in the kidney tubules [6].
• Protection by testosterone propionate against the nephrotoxicity of 2-aminoanthraquinone in Fischer rats [7].

References